Vera Salus Ricerca

A study published in 𝘚𝘤𝘪𝘦𝘯𝘤𝘦 reports an innovative mucosal vaccination strategy that protects against various respiratory pathogens. The work highlights an intranasal vaccine approach designed to stimulate both systemic and mucosal immune responses, and might represent a new strategy for broad respiratory protection during future pandemics.
https://www.science.org/doi/10.1126/science.aea1260

La Food and Drug Administration (FDA) degli Stati Uniti ha approvato l'immuno-checkpoint inhibitor durvalumab (Imfinzi), di AstraZeneca, in combinazione con Bacillus Calmette-Guerin (BCG) per pazienti adulti con carcinoma vescicale non muscolo‑invasivo ad alto rischio (NMIBC) e BCG‑naïve. La terapia si è dimostrata efficace negli studi clinici, aumentando il disease‑free survival dei pazienti.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder

A research study published in the journal 𝘗𝘳𝘰𝘤𝘦𝘦𝘥𝘪𝘯𝘨𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘕𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘈𝘤𝘢𝘥𝘦𝘮𝘺 𝘰𝘧 𝘚𝘤𝘪𝘦𝘯𝘤𝘦𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴 𝘰𝘧 𝘈𝘮𝘦𝘳𝘪𝘤𝘢 demonstrated that, after whole-genome duplication (WGD) events, the exact geometric distribution of homologous chromosomes in daughter cells determines their cell fate, including differentiation, tumorigenesis or aging.
https://www.pnas.org/doi/10.1073/pnas.2524135123

Regeneron ha siglato un accordo del valore potenziale di 2,3 miliardi di dollari ($2.3B) con Parabilis per la sua piattaforma Helicon. L'intento è quello di sviluppare Antibody–Helicon Conjugates (AHCs), concettualmente simili agli ADCs (antibody-drug conjugates), progettati per bersagliare target intracellulari difficili da regolare. L'accordo prevede investimenti di $50M come anticipo, più $75M in equity ed altri al raggiungimento di specifici milestones fino a $2.2B.
https://www.fiercebiotech.com/biotech/regeneron-pens-23b-pact-parabilis-develop-new-type-adc-therapy

A research study published in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘕𝘢𝘯𝘰𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 describes a novel methodology for nanometre resolution microscopy of the glycocalyx surrounding cellular compartments within tissues. This techinique, that the Authors called glycan atlassing, could enable nanoscale mapping of glycocalyx structures to obtain original information on cell states and diseases.
https://www.nature.com/articles/s41565-026-02151-y

La Food and Drug Administration (FDA) degli Stati Uniti ha approvato Veppanu (vepdegestrant), sviluppato da Arvinas e Pfizer, per il trattamento del carcinoma mammario (BC) ER‑positivo/HER2‑negativo con mutazione ESR1, in pazienti già trattati con almeno una linea endocrina. Veppanu è la prima terapia basata su tecnologia PROTAC (PROteolysis TArgeting Chimera) a ottenere l’approvazione regolatoria da parte dell'FDA. Il PROTAC sfrutta un meccanismo farmacologico di degradazione proteica mirata, in cui una molecola bifunzionale recluta la proteina bersaglio per la sua eliminazione attraverso il sistema ubiquitina‑proteasoma.
https://www.fiercepharma.com/pharma/fda-hands-pfizer-arvinas-veppanu-early-approval-certain-breast-cancer

A research study published in the journal 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘦𝘭𝘭 suggests a mechano-inflammatory pathway may promote genomic instability and carcinogenesis in stiff tissues. In fact, tissue tension could activate epithelial STAT3-driven chemokine release with macrophage recruitment, which induces lipid aldehyde-dpendent epithelial DNA damage and neoplastic transformation.
https://www.cell.com/cancer-cell/fulltext/S1535-6108(26)00176-5

A new study published in the journal 𝘚𝘤𝘪𝘦𝘯𝘤𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺 demonstrated that, in the tumour microenvironment, depletion of the metabolite citraconate in CD8 T cells contributes to cancer immuno-evasion. Citraconate supplementation restores T cell stemness and anticancer functions by activating cAMP and protein kinase A (PKA) signaling.
https://www.science.org/doi/10.1126/sciimmunol.adz0348

Eli Lilly (Lilly) ha acquisito Kelonia Therapeutics (Kelonia) in un’operazione dal valore potenziale fino a 7 miliardi di dollari. Kelonia ha sviluppato piattaforme CAR-T oncologiche peculiari, caratterizzate dalla capacità di riprogrammare in vivo i linfociti T dei pazienti. Dopo somministrazione endovenosa singola, le tecnologie di Kelonia consentono di generare le cellule CAR‑T direttamente nell’organismo umano, senza passaggi preliminari ex vivo.
https://www.cnbc.com/2026/04/20/eli-lilly-to-acquire-cancer-drug-maker-kelonia.html

A research study published in 𝘊𝘢𝘯𝘤𝘦𝘳 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 demonstrated that the homeodomain HOXD13 is a trascription factor promoting melanoma development by driving tumor angiogenesis and immune evation.
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-1853/772176/A-targetable-developmental-program-co-regulates